Home
Clinical Trials
NCT00078403

Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)

Last Updated: 2021-11-08

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

333 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-07-31

Study Completion Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Infection with both HIV and hepatitis C virus (HCV) may result in serious and sometimes fatal liver disease. The purpose of this study was to test the effectiveness of long-term pegylated interferon alfa-2a (PEG-IFN) and ribavirin treatment in slowing liver disease progression in people infected with both HIV and HCV.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rapid progression of liver disease to liver failure has been observed in people coinfected with HIV and HCV. This observation appears to be directly related to an increase in the rate of fibrotic progression in the liver compared to people infected with HCV alone. PEG-IFN and ribavirin are used in standard treatment of HCV. This study tested the effectiveness of using PEG-IFN in reducing the rate of liver fibrosis progression in participants coinfected with HIV and HCV who could not lower their HCV viral load to undetectable or who could not maintain their HCV viral load at undetectable on PEG-IFN and ribavirin treatment.

Participants entered Step 1 (initial run-in period) to receive 12 weeks of 180 mcg PEG-IFN subcutaneously once weekly plus 1 to 1.2 g/day ribavirin based on body weight. At week 12, HCV RNA testing was performed.

Participants with early virologic response (EVR), defined as \>=2 log10 drop in HCV RNA from baseline or undetectable HCV RNA (\<600 IU/ml with quantitative assay used in Step 1) at Week 12, who had tolerated Step 1 treatment, entered into Step 3 to continue receiving the Step 1 treatment for a total of 72 weeks (Arm C). Participants who did not meet the criteria for entry into Step 3 were discontinued from the study. In Step 3, participants were followed for an additional 24 weeks after treatment discontinuation to determine sustained virologic response (SVR). Initially, Step 3 participants who had a detectable HCV viral load (\>=60 IU/ml with the qualitative assay used in Step 3) at Week 36 were eligible to enroll in Step 2. After early closure of Step 2, such participants remained in Step 3 until study completion.

Participants with \<2 log10 drop in HCV RNA from baseline and detectable HCV RNA at Week 12 (non-EVR) discontinued Step 1 treatment. Non-EVRs who met the Step 2 eligibility criteria, were enrolled in Step 2 and randomized to receive 180 mcg PEG-IFN subcutaneously weekly for 72 weeks (Arm A) or observation for 72 weeks (Arm B). Participants who did not meet the criteria for entry into Step 2 were discontinued from the study. Step 2 of the study was closed prematurely in May 2007 due to lower than expected progression rates among the participants in the observation arm such that the primary objective could not be reached. There were no safety concerns.

Liver biopsies were conducted at study screening, and at Step 2 entry and exit until the early closure of Step 2. Medical history assessment, physical exams, and blood collection were conducted every 4-12 weeks for participants in Steps 1, 2, and 3. Participants were followed for up to 18 weeks in Step 1, followed by a total of 72 in Step 2 or by up to a total of 84 weeks in Step 3.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections Hepatitis C Liver Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Treatment Experienced

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)

At week 12 (end of the initial run-in period - Step 1) participants were found to have detectable HCV RNA (HCV RNA \>=600 IU/mL) and had less than a 2 log10 decrease in HCV RNA from baseline. For Step 2, participants were randomized to receive the pegylated interferon (PEG-IFN) 180 mcg weekly for 72 weeks.

Group Type EXPERIMENTAL

Peginterferon alfa-2a

Intervention Type DRUG

180 mcg PEG-IFN subcutaneously

Ribavirin

Intervention Type DRUG

One tablet or capsule containing ribavirin 200 mg

Arm B: OL (PEG-IFN, RBV) then OL Randomized (Observation)

Group Type EXPERIMENTAL

Peginterferon alfa-2a

Intervention Type DRUG

180 mcg PEG-IFN subcutaneously

Ribavirin

Intervention Type DRUG

One tablet or capsule containing ribavirin 200 mg

Arm C: OL (PEG-IFN, RBV) then OL (PEG-IFN, RBV)

At week 12 (end of initial run-in period, Step 1) participants were found to have undetectable HCV RNA (HCV RNA \<600 IU/mL) or at least a 2 log10 decrease in HCV RNA from baseline. Participants entered Step 3 and were assigned to continue the run-in treatment (PEG-IFN 180 mcg weekly \& RBV1-1.2 g/day based on weight) for a total of 72 weeks. At week 36, participants who had detectable HCV RNA (HCV RNA \>=60 IU/mL using a qualitative assay) could enter Step 2 and be randomized to OL PEG-IFN or Observation.

Group Type EXPERIMENTAL

Peginterferon alfa-2a

Intervention Type DRUG

180 mcg PEG-IFN subcutaneously

Ribavirin

Intervention Type DRUG

One tablet or capsule containing ribavirin 200 mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Peginterferon alfa-2a

180 mcg PEG-IFN subcutaneously

Intervention Type DRUG

Ribavirin

One tablet or capsule containing ribavirin 200 mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HIV infected
* Stable antiretroviral therapy for at least 8 weeks prior to study entry OR have not received any antiretroviral therapy for at least 4 weeks prior to entry
* HIV viral load less than 50,000 copies/ml within 6 weeks prior to study entry
* CD4 count greater than 200 cells/mm\^3 within 6 weeks prior to study entry
* Hepatitis C virus (HCV) infected
* Either HCV treatment naive OR previously treated with interferon (IFN), PEG-IFN, IFN and ribavirin, or PEG-IFN and ribavirin for at least 12 weeks and HCV RNA positive following their last course of HCV treatment
* Chronic liver disease consistent with chronic viral hepatitis
* At least stage I fibrosis on a liver biopsy obtained within 104 weeks of study entry
* If at stage VI fibrosis, Child-Pugh-Turcotte (CPT) score of 5 or less and no more than Child-Pugh Class A
* Liver enzyme (alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], and alkaline phosphatase) levels 10 times or less than upper limit of normal
* Agree to use acceptable methods of contraception

* Currently enrolled in Step 1 or received 12 weeks of PEG-IFN plus ribavirin outside this study
* Detectable HCV viral load and \<2 log10 decrease from baseline in plasma/serum HCV viral load at Week 12.
* On Step 1 study treatment for no longer than 18 weeks

* Currently enrolled in Step 1
* Undetectable HCV RNA or a 2-log or greater decrease in plasma/serum HCV viral load.
* On Step 1 study treatment for no longer than 18 weeks

Exclusion Criteria

* Have received HCV treatment within 4 weeks of study entry. Participants currently receiving treatment for HCV, if non-EVRs, were considered for direct entry into Step 2, without the run-in period in Step 1.
* Could not tolerate treatment with PEG-IFN, defined as missing 3 or more consecutive PEG-IFN doses during the first 12 weeks or a total of 5 doses prior to Step 3 entry. Participants who have missed doses of ribavirin will not be excluded from Step 3 entry.
* Use of granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) within 14 days prior to study entry
* Alpha feto protein level 400 ng/ml or greater within 24 weeks prior to study entry, or alpha feto protein level greater than 50 ng/ml and less than 400 ng/ml (unless computed tomography \[CT\] scan or magnetic resonance imaging \[MRI\] shows no evidence of hepatic tumor) within 24 weeks prior to study entry
* Decompensated liver disease, including presence or history of ascites, variceal bleeding, and brain or nervous system damage as a result of liver damage
* Other causes of significant liver disease, including hepatitis A or B, excess iron deposits in the liver (hemochromatosis), or homozygote alpha-1 antitrypsin deficiency
* Use of systemic corticosteroids, interferon gamma, TNF-alpha inhibitors, rifampin, rifabutin, pyrazinamide, isoniazid, ganciclovir, or hydroxyurea within 2 weeks prior to study entry
* Known allergy/sensitivity to PEG-IFN alfa-2a or ribavirin or their formulations
* History of uncontrolled seizure disorders
* Clinically active thyroid disease. Thyroid hormone replacement therapy is permitted, but thyroid-stimulating hormone (TSH) and free thyroxine index (FTI) must be in normal range.
* History of autoimmune processes, including Crohn's disease, ulcerative colitis, severe psoriasis, and rheumatoid arthritis, that may be made worse by interferon use
* Any systemic antineoplastic or immunomodulatory treatment or radiation within 24 weeks prior to study entry
* Malignancy
* Active coronary artery disease within 24 weeks prior to study entry
* Acute or active AIDS-defining opportunistic infections within 12 weeks of study entry
* Hemoglobin abnormalities (e.g., thalassemia) or any other cause of or tendency to break down red blood cells (hemolysis)
* History of major organ transplantation with an existing functional graft
* Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with study adherence
* Uncontrolled or active depression or other psychiatric disorder, such as untreated Grade 3 psychiatric disorder, medically untreatable Grade 3 disorder, or any hospitalization within 52 weeks of study entry that, in the opinion of the investigator, may interfere with study requirements
* Other serious illness or chronic medical condition that, in the opinion of the investigator, may have prevented participant's completion of the study
* Pregnant or breastfeeding

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kenneth E. Sherman, MD, PhD

Role: STUDY_CHAIR

University of Cincinnati

Raymond Chung, MD

Role: STUDY_CHAIR

Harvard/Massachusetts General Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alabama Therapeutics CRS

Birmingham, Alabama, United States

Site Status

University of Southern California CRS

Los Angeles, California, United States

Site Status

UCLA CARE Center CRS

Los Angeles, California, United States

Site Status

Stanford AIDS Clinical Trials Unit CRS

Palo Alto, California, United States

Site Status

UCSD Antiviral Research Center CRS

San Diego, California, United States

Site Status

Ucsf Hiv/Aids Crs

San Francisco, California, United States

Site Status

Santa Clara Valley Med. Ctr.

San Jose, California, United States

Site Status

University of Colorado Hospital CRS

Aurora, Colorado, United States

Site Status

Georgetown University CRS (GU CRS)

Washington D.C., District of Columbia, United States

Site Status

Univ. of Hawaii at Manoa, Leahi Hosp.

Honolulu, Hawaii, United States

Site Status

Northwestern University CRS

Chicago, Illinois, United States

Site Status

Indiana Univ. School of Medicine, Infectious Disease Research Clinic

Indianapolis, Indiana, United States

Site Status

Indiana Univ. School of Medicine, Wishard Memorial

Indianapolis, Indiana, United States

Site Status

Johns Hopkins University CRS

Baltimore, Maryland, United States

Site Status

Massachusetts General Hospital CRS (MGH CRS)

Boston, Massachusetts, United States

Site Status

Brigham and Women's Hosp. ACTG CRS

Boston, Massachusetts, United States

Site Status

Beth Israel Deaconess Med. Ctr., ACTG CRS

Boston, Massachusetts, United States

Site Status

Washington University Therapeutics (WT) CRS

St Louis, Missouri, United States

Site Status